{"id":"consolidation-iii-hidarac-cycle","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cerebellar syndrome (high-dose cytarabine toxicity)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine is a nucleoside analog that incorporates into DNA and RNA, disrupting synthesis and leading to cell death. The high-dose consolidation approach is used post-induction in acute myeloid leukemia (AML) to eliminate residual disease and improve long-term remission rates. This Phase 3 trial likely evaluates efficacy and safety of this consolidation strategy in AML patients.","oneSentence":"HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:28.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) consolidation therapy"}]},"trialDetails":[{"nctId":"NCT02072811","phase":"PHASE3","title":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"dr hab. n. med. Agnieszka Wierzbowska","startDate":"2014-02","conditions":"Acute Myeloid Leukemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Cytosine arabinoside [Ara-C]","- 2-CdA [Cladribine, 2-Chlorodeoxyadenosine]"],"phase":"phase_3","status":"active","brandName":"Consolidation, III HiDAraC cycle","genericName":"Consolidation, III HiDAraC cycle","companyName":"dr hab. n. med. Agnieszka Wierzbowska","companyId":"dr-hab-n-med-agnieszka-wierzbowska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML) consolidation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}